Mesco Pharma

MESCOPHARM10 Jan 2022

Pharmaceuticals

₹

0.00 (0.00%)

Lowest Today

Highest Today

Prev. Close

Today’s Open

52 Week High

52 Week Low

BUY

SELL

To Invest in Mesco Pharma

Mesco Pharma

Pharmaceuticals

MESCOPHARM10 Jan 2022

₹

0.00 (0.00%)

OverviewFundamentals

Corporate action

Peer comparison

Income Sheet

Balance sheet

Cash flow

Share holding

About Us

Corporate Action

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

All

Dividends

Bonus

Splits

Others

Ex-Date	Type	Description	Record Date
09-Nov-2023	BC	Trading Members of the Exchange are hereby informed that the undermentioned 6 companies that have remained suspended for more than 6 months would be delisted from the platform of the Exchange, with e	12-Nov-2023
12-May-2022	BC	This is in continuation to Exchange Notice No. 20211012-25 dated October 12, 2021 wherein the Trading Members were advised that w.r.t to the following companies, 15 days after suspension had been eff	24-May-2022
09-Feb-2022	BC	MESCO PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2022 inter alia to consider and approve 1. To consider and approve the stand	14-Feb-2022
20-Oct-2021	BC	Pursuant to the provisions of Circular No. SEBI/HO/CFD/CMD/CIR/P/2020/12 dated January 22, 2020 issued by Securities and Exchange Board of India (SEBI) with respect to Standard Operating Procedure (S	22-Nov-2021
12-Oct-2021	BC	Pursuant to the provisions of Circular No. SEBI/HO/CFD/CMD/CIR/P/2020/12 dated January 22, 2020 issued by Securities and Exchange Board of India (SEBI) with respect to Standard Operating Procedure (S	12-Nov-2021

No Rights has been declared by MESCOPHARM

Book Closure

Record Date	Split Date	Purpose
12-Nov-2023	-	Trading Members of the Exchange are hereby informed that the undermentioned 6 companies that have remained suspended for more than 6 months would be delisted from the platform of the Exchange, with e
24-May-2022	-	This is in continuation to Exchange Notice No. 20211012-25 dated October 12, 2021 wherein the Trading Members were advised that w.r.t to the following companies, 15 days after suspension had been eff
14-Feb-2022	-	MESCO PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2022 inter alia to consider and approve 1. To consider and approve the stand
22-Nov-2021	-	Pursuant to the provisions of Circular No. SEBI/HO/CFD/CMD/CIR/P/2020/12 dated January 22, 2020 issued by Securities and Exchange Board of India (SEBI) with respect to Standard Operating Procedure (S
12-Nov-2021	-	Pursuant to the provisions of Circular No. SEBI/HO/CFD/CMD/CIR/P/2020/12 dated January 22, 2020 issued by Securities and Exchange Board of India (SEBI) with respect to Standard Operating Procedure (S

Peer Comparison

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Scrip Name	Price	Daily Change	M.Cap (Cr)	1 Year Returns %	P/E (TTM)	PB Ratio
Mesco Pharmaceuticals Ltd ₹4.54(0.00/0.00%)	4.54	+0.00	9.23	-39.39	0.00	-0.88
Astrazeneca Pharma India Ltd ₹5,424.45(+90.60/1.70%)	5,424.45	+90.60	13,561.13	71.45	85.02	20.71
Bliss GVS Pharma Ltd ₹119.10(-10.10/-7.82%)	119.10	-10.10	1,246.87	56.07	18.27	1.28
Cipla Ltd ₹1,424.75(+5.20/0.37%)	1,424.75	+5.20	115,033.60	54.70	34.98	4.44
Amrutanjan Health Care Ltd ₹775.50(-11.10/-1.41%)	775.50	-11.10	2,242.02	27.78	50.95	8.56
Abbott India Ltd ₹26,144.45(-459.90/-1.73%)	26,144.45	-459.90	55,556.96	15.92	48.50	17.87

Income Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
Gross Sales	0.00	0.00	0.00	0.00	0.00	0.00
Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales	0.00	0.00	0.00	0.00	0.00	0.00
Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
Other Income	0.00	0.00	0.00	0.00	0.00	0.00
Total Income	0.00	0.00	0.00	0.00	0.00	0.00
Total Expenditure	0.00	0.00	0.00	0.00	0.00	0.00
PBIDT	0.00	0.00	0.00	0.00	0.00	0.00
Interest	0.00	0.00	0.00	0.00	0.00	0.00
PBDT	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation	0.00	0.00	0.00	0.00	0.00	0.00
Tax	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00
Reported Profit After Tax	0.00	0.00	0.00	0.00	0.00	0.00
Extra-ordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
Adjusted Profit After Extra-ordinary item	0.00	0.00	0.00	0.00	0.00	0.00

EPS (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
EPS (Adj) (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Calculated EPS (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Calculated EPS (Adj) (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Calculated EPS (Ann.) (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Calculated EPS (Adj) (Ann.) (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Book Value (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend (%)	0.00	0.00	0.00	0.00	0.00	0.00
Equity	19.74	19.74	19.74	19.74	19.74	19.74
Reserve & Surplus	0.00	0.00	0.00	0.00	0.00	0.00
Face Value	10.00	10.00	10.00	10.00	10.00	10.00

Public Shareholding (No. Of Shares)	0.00	0.00	0.00	0.00	0.00	0.00
Public Shareholding (% in Equity)	0.00	0.00	0.00	0.00	0.00	0.00

Pledged/Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

Non Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

PBIDTM(%)	0.00	0.00	0.00	0.00	0.00	0.00
PBDTM(%)	0.00	0.00	0.00	0.00	0.00	0.00
PATM(%)	0.00	0.00	0.00	0.00	0.00	0.00

Balance Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Mar 21	Mar 20	Mar 19	Mar 18	Mar 17	Mar 16
SOURCES OF FUNDS :
Share Capital	19.74	19.74	19.74	19.74	19.74	19.74
Reserves Total	-30.76	-30.75	-30.65	-30.24	-30.16	-29.90
Equity Share Warrants	0.00	0.00	0.00	0.00	0.00	0.00
Equity Application Money	0.00	0.00	0.00	0.00	0.00	0.00
Total Shareholders Funds	-11.02	-11.01	-10.91	-10.50	-10.42	-10.16
Secured Loans	0.00	0.00	0.00	0.00	0.00	0.00
Unsecured Loans	11.18	11.22	11.14	10.75	10.66	10.39
Total Debt	11.18	11.22	11.14	10.75	10.66	10.39
Total Liabilities	0.16	0.21	0.23	0.25	0.24	0.23
APPLICATION OF FUNDS :
Gross Block	0.18	0.18	0.18	0.18	19.56	19.56
Less : Accumulated Depreciation	0.00	0.00	0.00	0.00	19.38	19.38
Less:Impairment of Assets	0.00	0.00	0.00	0.00	0.00	0.00
Net Block	0.18	0.18	0.18	0.18	0.18	0.18
Lease Adjustment	0.00	0.00	0.00	0.00	0.00	0.00
Capital Work in Progress	0.00	0.00	0.00	0.00	0.00	0.00
Producing Properties	0.00	0.00	0.00	0.00	0.00	0.00
Investments	0.00	0.00	0.03	0.03	0.03	0.03
Current Assets, Loans & Advances	0.00	0.00	0.00	0.00	0.00	0.00
Inventories	0.00	0.00	0.00	0.00	0.00	0.00
Sundry Debtors	0.00	0.00	0.00	0.00	0.00	0.00
Cash and Bank	0.00	0.04	0.04	0.04	0.04	0.04
Loans and Advances	0.00	0.00	0.00	0.00	0.00	0.00
Total Current Assets	0.00	0.04	0.04	0.04	0.04	0.04
Less : Current Liabilities and Provisions	0.00	0.00	0.00	0.00	0.00	0.00
Current Liabilities	0.02	0.01	0.02	0.01	0.00	0.00
Provisions	0.00	0.00	0.00	0.00	0.00	0.01
Total Current Liabilities	0.02	0.01	0.02	0.01	0.00	0.01
Net Current Assets	-0.01	0.02	0.02	0.03	0.04	0.03
Miscellaneous Expenses not written off	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Assets	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Liability	0.00	0.00	0.00	0.00	0.00	0.00
Net Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00
Total Assets	0.17	0.20	0.23	0.24	0.25	0.24
Contingent Liabilities	0.00	0.00	0.00	0.00	0.00	0.00

Cash Flow

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

PARTICULARS	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017
Cash and Cash Equivalents at Beginning of the year	0.04	0.04	0.04	0.04	0.04
Net Cash from Operating Activities	0.00	-0.08	-0.39	-0.09	-0.26
Net Cash Used In Investing Activities	0.00	0.00	0.00	0.00	0.00
Net Cash Used In Financing Activities	-0.03	0.08	0.39	0.09	0.26
Net Inc./Dec In Cash And Cash Equivalents	-0.04	0.00	0.00	0.00	0.00
Cash And Cash Equivalents At End Of The Year	0.00	0.04	0.04	0.04	0.04

Share Holding

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Promoter Shareholding

39.30%

FII Shareholding

0.00%

DII Shareholding

0.00%

Public Shareholding

60.70%

**Promoter pledged shareholding 39.30%

About Mesco Pharmaceuticals Ltd

Mesco Pharmaceuticals Ltd is in the Pharmaceuticals sector, having a market capitalization of Rs. 9.23 crores. It has reported a sales of Rs. 0 crores and a net profit of Rs. 0 crores for the quarter ended December 2018. The company management includes , Dushyant Kumar Singh,N S Parameshwaran,Hawa Singh Chahar,Dhruv Singh (Mesco Pharmaceuticals Ltd) among others.

Chairman

Registered office

Upper Kesalton,Tallital,Nainital,Uttar Pradesh,263001

FAX :

Background

Incorporation Year1986

Face Value₹10

Market Lot1

How to buy Mesco Pharma shares on nse?

To buy Mesco Pharma shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified

What is the Mesco Pharma share price today?

The Mesco Pharma shares price on nse is Rs.4.54 today.

What is the market cap of Mesco Pharma shares on BSE ?

The company has a market capitalization of Rs.9.23Cr

What is the PE & PB ratio of Mesco Pharma shares ?

PE is 0 and PB is -0.88

What is the 52 Week High and Low of Mesco Pharma shares?

Mesco Pharma stock price high: Rs.4.54 Mesco Pharma stock price low: Rs.0